- Decipher Prostate test improves risk-stratification to help reduce under- and over-treatment - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 15, 2023-- Veracyte, Inc . (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology , Biology, Physics
Additional findings from G-MINOR trial reinforce clinical utility of Veracyte’s Decipher Prostate Genomic Classifier SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 13, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced new data being presented this week at the 2023 American Society of Clinical
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market on Wednesday, February 22, 2023 . Company management will host a conference call and
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 1, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking
Findings published in Frontiers in Endocrinology were derived from analyses of Veracyte’s comprehensive thyroid nodule database of whole transcriptome sequencing SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 1, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in
Meta-analysis of 13 independent studies suggests genomic test performs even better in real-world clinical practice as compared to original clinical validation study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that findings
Grew Total Revenue to $75.6 million , an Increase of 25% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022 .
- New findings reinforce potential of company’s multi-omics capabilities and tools in immuno-oncology to address biopharma partners’ unique oncology drug development needs - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 1, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 27, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Credit Suisse 31 st Annual Healthcare Conference on
Findings shared in an oral presentation at ASTRO Annual Meeting 2022 suggest predictive biomarker could help guide treatment in men experiencing disease progression after surgery SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 25, 2022-- Veracyte, Inc .
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
